Simplifying Global Compliance
FDAnews Drug Daily Bulletin
Xoma Lands Orphan Drug Status for Eye Disease Treatment
Aug. 24, 2012
Xoma lead drug, gevokizumab, was granted orphan drug status for an inflammatory eye disease. Gevokizumab, or XOMA-052, is a monoclonal antibody that focuses on shutting down inflammation brought on by a type of cell-signaling protein called interleukin-1 beta.
San Francisco Business Journal
Copyright ©2018. All Rights Reserved.
Design, CMS, Hosting & Web Development :: ePublishing